RESUMO
El rabdomiosarcoma es el tumor maligno de partes blandas más frecuente en la edad pediátrica. Puede afectar cualquier localización anatómica. El subtipo histológico alveolar suele causar lesiones en las extremidades en niños de mayor edad. Los sitios metástasicos más frecuentes son el pulmón, la médula ósea, el hueso y los ganglios linfáticos. Describimos el caso de un paciente con rabdomiosarcoma alveolar (RA) con metástasis cardíaca, una presentación poco frecuente de la patología.
Rhabdomyosarcoma is the most common malignant soft tissue tumor in pediatric age. It can affect any anatomical location. Alveolar histological subtype usually presents lesions on the extremities in older children. The most common metastatic sites are the lung, bone marrow, bone and lymph node. We describe a case of alveolar rhabdomyosarcoma with cardiac metastasis in a pediatric patient, a rare presentation of the pathology.
Assuntos
Humanos , Masculino , Criança , Neoplasias de Tecidos Moles/patologia , Rabdomiossarcoma Alveolar/patologia , Doenças do Pé/patologia , Neoplasias Cardíacas/secundário , Rabdomiossarcoma Alveolar/diagnóstico , Rabdomiossarcoma Alveolar/terapia , Septo Interventricular , Doenças do Pé/diagnóstico , Doenças do Pé/tratamento farmacológico , Neoplasias Cardíacas/diagnóstico , Neoplasias Cardíacas/tratamento farmacológico , Estadiamento de NeoplasiasRESUMO
BACKGROUND: Lyme borreliosis is a disease transmitted by ticks to mammals, especially in horses and humans. Caused by a spirochete Borrelia burgdorferi, it can result in lameness, arthritis, carditis, dermatitis and neurological signs. Anaphylactoid reactions are severe responses caused by direct action of substances (drugs, toxins), which can pose risks to life. Still poorly documented in horses, these reactions are caused by the effects of inflammatory mediators such as histamine, kinins and arachidonic acid metabolites. The last two are the most clinically relevant for the species. CASE PRESENTATION: The simultaneous occurrence of anaphylactoid reaction in two horses experimentally infected by Borrelia burgdorferi undergoing intravenous treatment with ceftriaxone sodium is reported. It was administered 4.7 × 10(8) spirochetes intradermal and subcutaneous applications in both horses to evaluate clinical aspects of the Lyme disease, 95 days before the application of sodium ceftriaxone. During the administration, one horse (a gelding) showed immediate and severe anaphylactoid symptoms such as urticaria, dyspnea, tachycardia, and eyelid edema, which were controlled by injecting dexamethasone. After 1 day, it expressed signs of abdominal discomfort, caused by severe bloat, which was treated surgically via celiotomy. Subsequently, this gelding had piroplasmosis and severe anemia, requiring treatment with an antimicrobial and blood transfusion. Second horse (a mare) showed signs of hypotension during the application of the antibiotic, which disappeared only when the application was interrupted. Days after the event, the mare developed moderate large colon bloat, which was treated with medication only. Subsequently the mare was evolved into the prodromal phase of laminitis in one of the forelimbs, which was treated for 10 days with non-steroidal anti-inflammatory and rheology modifying drugs and cryotherapy. CONCLUSIONS: From the two cases presented here, it does appear that sodium ceftriaxone can induce anaphylactoid reactions in horses infected by Borrelia burgdorferi, which may evolve into colic syndrome, laminitis and the occurrence of opportunistic infections. However, further evidence should be collected in order to draw definite conclusions.
Assuntos
Anafilaxia/veterinária , Borrelia burgdorferi , Ceftriaxona/efeitos adversos , Doenças dos Cavalos/induzido quimicamente , Doença de Lyme/tratamento farmacológico , Corticosteroides/uso terapêutico , Anafilaxia/induzido quimicamente , Anafilaxia/complicações , Anafilaxia/tratamento farmacológico , Animais , Antibacterianos/efeitos adversos , Anti-Inflamatórios não Esteroides/uso terapêutico , Ceftriaxona/uso terapêutico , Cólica/tratamento farmacológico , Cólica/etiologia , Cólica/cirurgia , Cólica/veterinária , Dexametasona/uso terapêutico , Feminino , Doenças do Pé/tratamento farmacológico , Doenças do Pé/etiologia , Doenças do Pé/veterinária , Casco e Garras , Doenças dos Cavalos/microbiologia , Cavalos , Inflamação/tratamento farmacológico , Inflamação/etiologia , Inflamação/veterinária , MasculinoRESUMO
UNLABELLED: The objective of this study was to evaluate the effects of botulinum toxin type A (BTX-A) on spastic foot in stroke patients in a rehabilitation program. METHOD: Hemiparetic stroke patients (n=21) enrolled in a rehabilitation program were divided into two groups. The first group (n=11) received a total of 300 UI BTX-A, and the second group (n=10) received 100 UI BTX-A. All patients were assessed at baseline and 2, 4, 8 and 12 weeks after injection for Modified Ashworth Score, time walking 10 meters, and the Functional Independence Measure (mFIM) motor score. RESULTS: The higher-dose group exhibited a significant improvement in spasticity, and both groups showed an improvement in time walking 10 meters and mFIM, with no significant differences between them. CONCLUSIONS: Our findings suggest that gains in gait velocity and functional independence were not correlated to BTX-A dose.
Assuntos
Toxinas Botulínicas Tipo A/uso terapêutico , Doenças do Pé/tratamento farmacológico , Fármacos Neuromusculares/uso terapêutico , Reabilitação do Acidente Vascular Cerebral , Atividades Cotidianas , Adulto , Feminino , Doenças do Pé/etiologia , Marcha/efeitos dos fármacos , Humanos , Masculino , Pessoa de Meia-Idade , Atividade Motora/efeitos dos fármacos , Espasticidade Muscular/tratamento farmacológico , Espasticidade Muscular/etiologia , Espasticidade Muscular/fisiopatologia , Estatísticas não Paramétricas , Acidente Vascular Cerebral/complicações , Fatores de Tempo , Resultado do Tratamento , Caminhada/fisiologiaRESUMO
The objective of this study was to evaluate the effects of botulinum toxin type A (BTX-A) on spastic foot in stroke patients in a rehabilitation program. Method: Hemiparetic stroke patients (n=21) enrolled in a rehabilitation program were divided into two groups. The first group (n=11) received a total of 300UI BTX-A, and the second group (n=10) received 100 UI BTX-A. All patients were assessed at baseline and 2, 4, 8 and 12 weeks after injection for Modified Ashworth Score, time walking 10 meters, and the Functional Independence Measure (mFIM) motor score. Results: The higher-dose group exhibited a significant improvement in spasticity, and both groups showed an improvement in time walking 10 meters and mFIM, with no significant differences between them. Conclusions: Our findings suggest that gains in gait velocity and functional independence were not correlated to BTX-A dose. .
O objetivo deste estudo foi avaliar os efeitos da toxina botulínica tipo A (TXB-A) sobre a espasticidade de membro inferior em pacientes pós-AVE em reabilitação. Método: 21 pacientes hemiparéticos foram divididos em dois grupos que receberam doses de TXB-A de 300UI (Grupo 1) e 100UI (Grupo 2) e foram avaliados antes da injeção e 2, 4, 8 e 12 semanas após, quanto à escala de Ashworth modificada, tempo para andar 10 metros e escore motor da Medida de Independência Funcional (MIFm). Resultados: O grupo que utilizou dose mais alta teve melhora significativa da espasticidade. Ambos os grupos tiveram melhora do tempo para andar 10 metros e da MIFm sem diferença significativa entre eles. Conclusões: A melhora da velocidade de marcha e da independência funcional não foram correlacionadas com a dose de TXB-A na amostra analisada. .
Assuntos
Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Toxinas Botulínicas Tipo A/uso terapêutico , Doenças do Pé/tratamento farmacológico , Fármacos Neuromusculares/uso terapêutico , Acidente Vascular Cerebral/reabilitação , Atividades Cotidianas , Doenças do Pé/etiologia , Marcha/efeitos dos fármacos , Atividade Motora/efeitos dos fármacos , Espasticidade Muscular/tratamento farmacológico , Espasticidade Muscular/etiologia , Espasticidade Muscular/fisiopatologia , Estatísticas não Paramétricas , Acidente Vascular Cerebral/complicações , Fatores de Tempo , Resultado do Tratamento , Caminhada/fisiologiaRESUMO
The number of people who travel internationally with their pets is increasing. Consequently, veterinarians around the world are more likely to encounter parasitic diseases formerly restricted to certain geographical locations. The purpose of this report is to describe a case of tungiasis, a disease caused by the sand flea Tunga penetrans, in a dog imported from Brazil to Denmark. To the best of the authors' knowledge, this is the first report of canine T. penetrans infestation in Scandinavia.
Assuntos
Doenças do Cão/parasitologia , Ectoparasitoses/veterinária , Doenças do Pé/veterinária , Sifonápteros , Animais , Brasil/epidemiologia , Dinamarca/epidemiologia , Doenças do Cão/diagnóstico , Doenças do Cão/tratamento farmacológico , Doenças do Cão/epidemiologia , Cães , Ectoparasitoses/diagnóstico , Ectoparasitoses/tratamento farmacológico , Ectoparasitoses/epidemiologia , Feminino , Doenças do Pé/diagnóstico , Doenças do Pé/tratamento farmacológico , Doenças do Pé/epidemiologia , Inseticidas/uso terapêutico , Ivermectina/uso terapêutico , ViagemRESUMO
An unusual case of a 3-year-old girl with a brucellar foot abscess is reported. Although direct microscopic examination of samples from the lesion did not reveal micro-organisms of any kind, a 7 day culture of caseous material yielded small colonies of Gram-negative cocobacilli in Löwenstein-Jensen medium. These were biochemically and molecularly identified as Brucella melitensis. The possibility of foot abscess being caused by Brucella should be considered in countries where brucellosis is endemic.
Assuntos
Abscesso/microbiologia , Brucella melitensis/isolamento & purificação , Brucelose/diagnóstico , Doenças do Pé/microbiologia , Abscesso/tratamento farmacológico , Antibacterianos/uso terapêutico , Brucelose/tratamento farmacológico , Brucelose/patologia , Pré-Escolar , Feminino , Doenças do Pé/tratamento farmacológico , HumanosRESUMO
BACKGROUND: Homeopathic Rhus toxicodendron (Rhus tox) is used in various inflammatory conditions. We screened its effect compared to succussed ethanol controls and appropriate active controls. METHOD: We initially experimented with Rhus tox 6, 12, 30 and 200 cH, using carrageenan-induced paw oedema in rats. The 6 cH dilution appeared most effective and was used in subsequent assays. We used pre-treatment and single treatment regimes in Wistar rats, and mice. RESULTS: We found significant reductions compared to control in carrageenan-induced paw oedema, vascular permeability, writhing induced by intraperitoneal acetic acid and stress induced gastric lesions. CONCLUSIONS: Rhus tox in homeopathic dilution appears to interfere with inflammatory processes involving histamine, prostaglandins and other inflammatory mediators.
Assuntos
Anti-Inflamatórios não Esteroides/farmacologia , Edema/tratamento farmacológico , Doenças do Pé/tratamento farmacológico , Homeopatia/métodos , Fitoterapia , Rhus , Toxicodendron , Administração Oral , Animais , Permeabilidade Capilar/efeitos dos fármacos , Carragenina , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Edema/induzido quimicamente , Doenças do Pé/induzido quimicamente , Masculino , Camundongos , Dor/prevenção & controle , Medição da Dor , Ratos , Ratos Wistar , Úlcera Gástrica/prevenção & controleRESUMO
BACKGROUND: Mycetoma is a chronic infection caused by aerobic actinomycetes and filamentous fungi. It is an occupational disease frequent in tropical countries and is uncommon in children. METHODS: A retrospective (25 years) report of mycetomas was conducted in children less than 15 years of age. Each of the cases was studied clinically and proven with microbiologic tests: direct examinations (to identify and classify the grains), cultures and identification based on morphology and biochemical tests. The therapeutic experience of the cases was also reviewed. RESULTS: In a 25-year period, a total of 334 mycetomas were seen at our institution, 15 of which (4.5%) were in patients 15 years of age and younger (mean age: 11.2 years, age range: 6-15 years). Twelve cases were males and 3 females. The main clinical location was the foot in 10 of 15 (66.6%). Etiologies included 13 actinomycetomas and 2 eumycetomas. Etiologic agents were Nocardia brasiliensis in 12 cases, Nocardia asteroides in one and Madurella mycetomatis in 2. Eleven of the13 cases of actinomycetomas treated with trimethoprim-sulfamethoxazole plus diaminodiphenylsulfone were cured. The 2 failures were successfully treated with amoxicillin/clavulanate. One of the eumycetomas was cured with itraconazole therapy, whereas the other failed various treatments eventuating in surgical amputation. CONCLUSIONS: Mycetomas are exceptional in children; in our setting, actinomycetomas are more frequent than eumycetomas. The clinical and microbiologic diagnosis is simple. Overall, treatment response is better for actinomycetomas than for eumycetomas.
Assuntos
Madurella/isolamento & purificação , Micetoma/microbiologia , Nocardia/isolamento & purificação , Adolescente , Criança , Feminino , Doenças do Pé/diagnóstico , Doenças do Pé/tratamento farmacológico , Doenças do Pé/microbiologia , Humanos , Masculino , Micetoma/diagnóstico , Micetoma/tratamento farmacológico , Nocardiose/diagnóstico , Nocardiose/tratamento farmacológico , Nocardiose/microbiologia , Nocardia asteroides/isolamento & purificação , Estudos RetrospectivosAssuntos
Doenças do Pé/parasitologia , Larva Migrans/diagnóstico , Adulto , Albendazol/uso terapêutico , Antiparasitários/uso terapêutico , Praias , Feminino , Doenças do Pé/diagnóstico , Doenças do Pé/tratamento farmacológico , Humanos , Ivermectina/uso terapêutico , Jamaica , Larva Migrans/tratamento farmacológico , Viagem , Clima TropicalRESUMO
Bovine Cu,Zn-SOD was chemically modified with an end-group aminated dextran derivative using a water-soluble carbodiimide as coupling agent. The enzyme retained 81% of the initial catalytic activity after the attachment of about 4.4 mol of polymer per protein subunit. The anti-inflammatory activity of the SOD was two times increased after conjugation with dextran. The modified enzyme was remarkably more resistant to inactivation by H(2)O(2) and its plasma half-life time was prolonged from 4 min to 3.2 h.